# Assessment of the Safety and Efficacy of RGN-259 Ophthalmic Solutions for Dry Eye Syndrome: ARISE-3

> **NCT03937882** · PHASE3 · COMPLETED · sponsor: **ReGenTree, LLC** · enrollment: 700 (actual)

## Conditions studied

- Dry Eye Syndromes
- Dry Eye

## Interventions

- **DRUG:** RGN-259
- **DRUG:** Placebo

## Key facts

- **NCT ID:** NCT03937882
- **Lead sponsor:** ReGenTree, LLC
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2019-05-24
- **Primary completion:** 2020-11-08
- **Final completion:** 2021-10-07
- **Target enrollment:** 700 (ACTUAL)
- **Last updated:** 2022-05-09


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT03937882

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT03937882, "Assessment of the Safety and Efficacy of RGN-259 Ophthalmic Solutions for Dry Eye Syndrome: ARISE-3". Retrieved via AI Analytics 2026-06-25 from https://api.ai-analytics.org/clinical/NCT03937882. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*